Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission-A cross-sectional study.
children and adolescents
immunosuppression
nephrotic syndrome
quality of life
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
11
04
2019
revised:
19
06
2019
accepted:
24
06
2019
pubmed:
27
6
2019
medline:
30
10
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
Severe forms of idiopathic nephrotic syndrome (INS) require immunosuppressive therapy: oral treatment or intravenous therapy (rituximab, RTX). The main objective was to describe quality of life (QOL) in these specific patients. Cross-sectional, multicentre, observational study analysed QOL using a standardised questionnaire in children from 7 to 17 years, with a steroid-dependent or steroid-resistant INS in stable remission. The questionnaire consisted of 30 questions concerning physical and emotional well-being, self-esteem, family, friends, school and disease resulting in a global score of 0-100. A total of 110 patients with a mean age of 11.6 years from three French paediatric nephrology centres were included. A total of 71 patients had oral immunosuppressive treatment, 27 had RTX, and 12 had both. 13.6% of patients had a steroid-resistant INS. The mean number of relapses was 5.8. Seventy-eight patients answered the questionnaire. The global score in the whole study population was 74.7; 72.6 in the RTX group, 76.2 in the oral drugs group, (P = 0.49). The results of sub-dimension 'school' were statistically lower in RTX group (61.6 ± 19.5) compared with oral drugs group (71.4 ± 16; P = 0.02). Global QOL score was high in 'difficult-to-treat' patients with INS in stable remission on oral immunosuppressive or RTX treatment.
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2267-2273Informations de copyright
©2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
Références
Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629-639.
Dudzik B, Kaczmarczyk I, Radziszewski A, Sułowicz W. Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis. Przegl Lek. 2001;58(7-8):798-804.
Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant. 2008;23(3):910-913.
Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology. Lancet 1991;337(8757):1555-1557.
Donia AF, Amer GM, Ahmed HA, et al. Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol. 2002;17(5):355-358.
Barletta G-M, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2003;18(8):833-837.
Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2005;20(9):1265-1268.
Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308-1315.
Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384(9950):1273-1281.
Gipson DS, Selewski DT, Massengill SF, et al. Gaining the PROMIS perspective from children with nephrotic syndrome: a Midwest pediatric nephrology consortium study. Health Qual Life Outcomes. 2013;11:30.
Rüth E-M, Landolt MA, Neuhaus TJ, Kemper MJ. Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr. 2004;145(6):778-783.
Official journal of the international society of nephrology. KDIGO Guideline 2012.
Sellier-Leclerc A-L, Macher M-A, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25(6):1109-1115.
Sellier-Leclerc A-L, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27(3):1083-1089.
Stahl-Pehe A, Straßburger K, Castillo K, et al. Quality of life in intensively treated youths with early-onset type 1 diabetes: a population-based survey. Pediatr Diabetes. 2014;15(6):436-443.
Werkstetter KJ, Ullrich J, Schatz SB, Prell C, Koletzko B, Koletzko S. Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. J Crohns Colitis. 2012;6(6):665-673.
Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Qual Life Res. 2011;20(5):691-702.
Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. BMC Med Res Methodol. 2012;12:70.
Agrawal S, Krishnamurthy S, Naik BN. Assessment of quality of life in children with nephrotic syndrome at a teaching hospital in South India. Saudi J Kidney Dis Transplant. 2017;28(3):593-598.
Jacquin P, Levine M. Poor adherence in chronic conditions during adolescence: understand in order to act. Arch Pediatr. 2008;15(1):89-94.
Selewski DT, Troost JP, Massengill SF, et al. The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol. 2015;30(9):1467-1476.
Thomsen OO, Cortot A, Jewell D, et al. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Am J Gastroenterol. 2002;97(3):649-653.
Dodson JL, Gerson AC, Hsiao C-J, Kaskel FJ, Weiss RA, Furth SL. Parent perspectives of health related quality of life in adolescents with chronic kidney disease due to underlying urological disorders: an assessment using the Child Health Questionnaire-Parent Form 50. J Urol. 2008;180(4 Suppl):1700-1704.